Once Daily Everolimus Is Safe and Effective in De Novo Renal Transplant Recipients: Six-Month Results of a Pilot Study

Transplantation Proceedings

Volumn 42, Issue 4, 2010, Pages 1308-1311

  Favi, E ^a   Spagnoletti, G ^a   Gargiulo, A ^a   Salerno, M P ^a   Romagnoli, J ^a   Citterio, F ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CHOLESTEROL; EVEROLIMUS; METHYLPREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; SAFETY; SIROLIMUS; TIME FACTORS; TISSUE DONORS; TRIGLYCERIDES;

EID: 77952571017     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.03.099     Document Type: Article

References (10)

1. Vanrenterghem Y.F., Claes K., Montagnino G., et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 85 (2008) 209
2. Takemoto S.K., Pinsky B.W., Schnitzler M.A., et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 12 (2007) 2704
3. Kahan B.D., and Camardo J.S. Rapamycin: clinical results and future opportunities. Transplantation 72 (2001) 1181
4. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacologic properties in vitro and in vivo. Transplantation 64 (1996) 36
5. Vitko S., Margreiter R., Weimar W., et al., RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in the novo renal transplant patients. Am J Transplant 5 (2005) 2521
6. Nashan B., Curtis J., Ponticelli C., et al., 156 Study Group. Everolimus and reduced exposure cyclosporine in de novo renal transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78 (2004) 1332
7. Vitko S., Tedesco H., Eris J., Pascual J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626
8. Neumayer H.H., Paradis K., Korn A., et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 48 (1999) 694
9. Kahan B.D., Wong R.L., Carter C., et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 68 (1999) 1100
10. Tedesco-Silva Jr. H., Vitko S., Pascual J., et al., 2306 and 2307 study groups. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 20 (2007) 27